Here are relevant reports on : nuclear-medicine-market
-
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium–201(Tl-201), gallium–67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.
- Published: May 2013
- Price: $ 4950
- TOC Available:
-
European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Thyroid, Cardiology), Procedures - Forecasts to 2020
Over the years, the European nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The European radiopharmaceuticals market is witnessing growth owing to an increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 radioisotopes are estimated to contribute the highest to the European nuclear medicine diagnostic market in 2015, whereas Ra-223, I-131 and Y-90 ensured their leading position in the therapeutic market. The European nuclear medicine/radiopharmaceuticals market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, growing at a CAGR of 8.2% from 2015 to 2020.
- Published: November 2015
- Price: $ 4950
- TOC Available:
-
Advanced Visualization Market by Type (Enterprise, Standalone), Modality (MRI, CT, PET, Ultrasound, Radiotherapy, Nuclear Medicine), Application (Radiology, Oncology, Neuro), End User (Hospital, ASC, Diagnostic Center) & Region - Global Forecast to 2029
The global advanced visualization market, valued at US$3.36 billion in 2023, stood at US$3.78 billion in 2024 and is projected to advance at a resilient CAGR of 11.7% from 2024 to 2029, culminating in a forecasted valuation of US$6.55 billion by the end of the period. Technological advancements in advanced visualization tools, the rising need for early detection of diseases, and the growing support from government & private organizations are key factors driving the market growth.
- Published: January 2025
- Price: $ 4950
- TOC Available:
-
Nuclear Medicine Software Market by Software (Image Management, Workflow, PACS, Dosimetry, Treatment, AI/Analytics), Application (Diagnosis, Treatment, Theranostics, Research), Disease (Onco, Neuro, Cardio), End User & Region - Global Forecast to 2030
The global nuclear medicine software market, valued at US$887.5million in 2024, stood at US$970.0 million in 2025 and is projected to advance at a resilient CAGR of 9.0% from 2025 to 2030, culminating in a forecasted valuation of US$1,491.5 million by the end of the period. This growth is mainly driven by the increasing demand for early and accurate diagnostics, as precision imaging is essential for treatment planning.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Personalized Medicine Market by Product (Personalized Medicine Testing, Personalized Medicine Therapeutics), Application (Oncology, Neurology, Cardiology) - Global Forecast to 2027
The global personalized medicine market is projected to reach USD ~500 billion by 2027 from USD 300 Billion in 2022, at a CAGR of 11% during the forecast period
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Europe Nuclear Medicine Market by Type (SPECT [Tc99m, I-123], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90, I-131], Brachytherapy), Application (Onco, Cardio), Procedure, End User (Imaging Center, Hospital) - Forecast to 2030
The Europe nuclear medicine market, valued at USD 2.14 billion in 2024, stood at USD 2.47 billion in 2025 and is projected to advance at a resilient CAGR of 15.8% from 2025 to 2030, culminating in a forecasted valuation of USD 5.15 billion by the end of the period. This growth is driven by the rising application of radiopharmaceuticals and radioisotopes for diagnostic imaging and targeted radionuclide therapies, especially in oncology, cardiology, and neurology. The major drivers of the demand include rising cancer incidence, the aging population, and the high adoption of the PET and SPECT procedures in key European nations.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90], Brachytherapy), Application (Onco, Thyroid, Cardio), Procedure, End User (Imaging Center, Hospital) - Forecast to 2030
The Asia Pacific nuclear medicine market, valued at USD 1.82 billion in 2024, stood at USD 2.13 billion in 2025 and is projected to advance at a resilient CAGR of 17.1% from 2025 to 2030, culminating in a forecasted valuation of USD 4.68 billion by the end of the period.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
North American Nuclear Medicine Market / Radiopharmaceuticals Market Size by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) & Region - Global Forecast to 2024
North american nuclear medicine market growth is primed to transition from $2.2 billion in 2019 to $2.7 billion by 2024, showcasing a strong CAGR of 4.1%. Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.
- Published: January 2020
- Price: $ 4950
- TOC Available:
-
Nuclear Medicine Market by Type [SPECT (Tc-99m, I-123, Ga-67), PET (F-18), Alpha Emitters, Beta Emitters (Y-90, Lu-177), Brachytherapy], Application (Oncology, Cardiology, Neurology), Procedure, End User (Imaging Center, Hospital), and Region -Global Forecast to 2030
The global nuclear medicine market, valued at USD 9.03 billion in 2024, stood at USD 10.41 billion in 2025 and is projected to advance at a resilient CAGR of 15.1% from 2025 to 2030, culminating in a forecasted valuation of USD 21.01 billion by the end of the period. The growth of the market is driven by the rising prevalence of cancer and cardiovascular diseases, which is accelerating the demand for diagnostic and therapeutic radiopharmaceuticals and medical radioisotopes.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
US Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18], Alpha Emitters, Beta Emitters [Y-90, Lu-177]), Application (Onco, Neuro), Procedure, End User (Imaging Center, Hospital), Radioisotope, Market Share, Growth - Forecast to 2030
The US Nuclear Medicine market, valued at USD 4.19 billion in 2024, stood at USD 4.81 billion in 2025 and is projected to advance at a resilient CAGR of 14.7% from 2025 to 2030, culminating in a forecasted valuation of USD 9.56 billion by the end of the period. This growth is attributed to the rapid expansion of theranostics and radioligand therapies, growing FDA approval of novel radiopharmaceuticals, and active clinical research at the US hospitals and academic medical centers.
- Published: April 2026
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
